3:13 PM
 | 
Nov 09, 2017
 |  BC Extra  |  Company News

Anthem updates Yescarta, Exondys 51 coverage

Anthem Inc. (NYSE:ANTM) said it will cover newly approved chimeric antigen receptor (CAR) T therapy Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) for certain patients. The firm also said it will now cover Exondys 51 eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT), reversing its initial decision to not cover the Duchenne muscular dystrophy (DMD) drug last year.

In a coverage policy note, Anthem said Yescarta is "medically necessary" to treat non-Hodgkin's lymphoma (NHL) only for adult patients with relapsed or refractory disease and a confirmed diagnosis of diffuse large B cell lymphoma (DLBCL), high-grade B cell lymphoma, primary mediastinal large B...

Read the full 523 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >